Myriad Genetics to Present Three Studies at the 2017 National Society of Genetic Counselors Annual Conference
September 12 2017 - 7:05AM
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular
diagnostics and personalized medicine, today announced that it will
present results from three studies at the National Society of
Genetic Counselors (NSGC) Annual Conference to be held September
13-16, 2017, in Columbus, OH. Importantly, Myriad will
present results from a study with 17,205 patients designed to
validate a panel of single nucleotide polymorphisms (SNPs) across
the entire human genome that are associated with increased breast
cancer risk.
“As we announced earlier this month, we launched an exciting new
product called riskScore™ to help women who test negative for a
hereditary mutation understand their remaining 5-year and lifetime
risk for developing breast cancer. This important new product
underscores Myriad’s commitment to scientific discovery and
innovation, and expands our leadership in hereditary cancer
testing,” said Johnathan Lancaster, M.D., Ph.D., chief medical
officer, Myriad Genetics. “In addition to presenting exciting
new data on riskScore at NSGC this year, we also will present
important research regarding variant classification from our myRisk
Hereditary Cancer test.”
A list of Myriad presentations at NSGC 2017 is below. More
information about the company’s presentations can be found at:
http://www.nsgc.org/conference. Follow Myriad on Twitter via
@MyriadGenetics and stay informed about conference news and updates
by using the hashtag #NSGC17.
Title |
Author
|
Poster/Abstract Number |
Day/Time |
MyriadProduct |
Podium Presentation
|
|
|
|
|
Development and Validation
of a Residual RiskScore to Predict Breast Cancer Risk inUnaffected
Women Negative for Mutations on a Multi-Gene
Hereditary Cancer Panel |
Elisha Hughes |
Platformpresentation#1131 |
Saturday,Sept. 16,2017:
11:30- 11:45 a.m.EDT. |
MyriadmyRiskwithriskScore |
Variant Reclassification
in a Clinical Cohort: ADecade of Experience |
NicholeBrown |
PlatformPresentation#1394 |
Friday, Sept. 15,2017:
3:15-3:30 p.m.EDT. |
MyriadmyRisk |
Poster
Presentations |
|
|
|
|
Hereditary cancer panel
testing allows ascreening opportunity for Hereditary Breast and
Ovarian Cancer and Lynch Syndromeregardless of the testing
indication |
Julie Culver |
Poster
|
Thursday,Sept. 14,2017:
5:45-7:00 p.m.EDT |
MyriadmyRisk |
|
|
|
|
|
About
riskScore™riskScore is a new
clinically validated personalized medicine tool that enhances
Myriad’s myRisk® Hereditary Cancer test. riskScore helps to
further predict a women’s lifetime risk of developing breast cancer
using clinical risk factors and genetic-markers throughout the
genome. The test incorporates data from greater than 80 single
nucleotide polymorphisms identified through 20 years of genome wide
association studies in breast cancer and was validated in our
laboratory to predict breast cancer risk. This data is then
combined with a best-in-class family and personal history
algorithm, the Tyrer-Cuzick model, to provide every patient with
individualized breast cancer risk. riskScore is offered
free-of-charge as an added service to Myriad’s myRisk Hereditary
Cancer test.
About Myriad myRisk® Hereditary
Cancer The Myriad myRisk Hereditary Cancer test uses an
extensive number of sophisticated technologies and proprietary
algorithms to evaluate 28 clinically significant genes associated
with eight hereditary cancer sites including: breast, colon,
ovarian, endometrial, pancreatic, prostate and gastric cancers and
melanoma.
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
five strategic imperatives: stabilizing hereditary cancer
revenue, growing new product volume, expanding reimbursement
coverage for new products, increasing RNA kit revenue
internationally and improving profitability with Elevate
2020. For more information on how Myriad is making a
difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer,
myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx,
myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore and
Prolaris are trademarks or registered trademarks of Myriad
Genetics, Inc. or its wholly owned subsidiaries in the United
States and foreign countries. MYGN-F, MYGN-G.
Safe Harbor StatementThis press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements relating to data being presented at the at the 2017
National Society of Genetic Counselors Annual Conference being held
September 13-16, 2017 in Columbus, OH; the ability of the riskScore
test to help women who test negative for a hereditary mutation
understand their remaining 5-year and lifetime risk for developing
breast cancer; Myriad’s commitment to scientific discovery and
innovation, and leadership in hereditary cancer testing; research
regarding variant classification concerning our myRisk Hereditary
Cancer test; and the Company’s strategic directives under the
caption “About Myriad Genetics.” These “forward-looking statements”
are based on management’s current expectations of future events and
are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those
described or implied in the forward-looking statements. These risks
include, but are not limited to: the risk that sales and profit
margins of our existing molecular diagnostic tests and
pharmaceutical and clinical services may decline or will not
continue to increase at historical rates; risks related to our
ability to transition from our existing product portfolio to our
new tests; risks related to changes in the governmental or private
insurers’ reimbursement levels for our tests or our ability to
obtain reimbursement for our new tests at comparable levels to our
existing tests; risks related to increased competition and the
development of new competing tests and services; the risk that we
may be unable to develop or achieve commercial success for
additional molecular diagnostic tests and pharmaceutical and
clinical services in a timely manner, or at all; the risk that we
may not successfully develop new markets for our molecular
diagnostic tests and pharmaceutical and clinical services,
including our ability to successfully generate revenue outside the
United States; the risk that licenses to the technology underlying
our molecular diagnostic tests and pharmaceutical and clinical
services tests and any future tests are terminated or cannot be
maintained on satisfactory terms; risks related to delays or other
problems with operating our laboratory testing facilities; risks
related to public concern over genetic testing in general or our
tests in particular; risks related to regulatory requirements or
enforcement in the United States and foreign countries and changes
in the structure of the healthcare system or healthcare payment
systems; risks related to our ability to obtain new corporate
collaborations or licenses and acquire new technologies or
businesses on satisfactory terms, if at all; risks related to our
ability to successfully integrate and derive benefits from any
technologies or businesses that we license or acquire, including
but not limited to our acquisition of Assurex, Sividon and the
Clinic; risks related to our projections about the potential market
opportunity for our products; the risk that we or our licensors may
be unable to protect or that third parties will infringe the
proprietary technologies underlying our tests; the risk of
patent-infringement claims or challenges to the validity of our
patents; risks related to changes in intellectual property laws
covering our molecular diagnostic tests and pharmaceutical and
clinical services and patents or enforcement in the United States
and foreign countries, such as the Supreme Court decision in the
lawsuit brought against us by the Association for Molecular
Pathology et al; risks of new, changing and competitive
technologies and regulations in the United States and
internationally; the risk that we may be unable to comply with
financial operating covenants under our credit or lending
agreements; the risk that we will be unable to pay, when due,
amounts due under our credit or lending agreements; and other
factors discussed under the heading “Risk Factors” contained in
Item 1A of our most recent Annual Report on Form 10-K, which has
been filed with the Securities and Exchange Commission, as well as
any updates to those risk factors filed from time to time in our
Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.
Media Contact:Ron Rogers(801) 584-3065rrogers@myriad.com
Investor Contact:Scott Gleason(801)
584-1143sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2024 to May 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From May 2023 to May 2024